Trials / Completed
CompletedNCT03718299
A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
An Open-Label, Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Moderate to Severe Plaque Psoriasis
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 55 (actual)
- Sponsor
- Sun Pharmaceutical Industries Limited · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of 10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40, Week 52 and Week 64, with subjects receiving tildrakizumab injections at Week 0, Week 4, Week 16, Week 28, Week 40, and Week 52. The total study duration will be approximately 64 weeks, excluding a screening period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Injections of tildrakizumab | given at Week 0, Week 4, Week 16, Week 28, Week 40 and Week 52 |
Timeline
- Start date
- 2019-07-16
- Primary completion
- 2021-11-02
- Completion
- 2021-11-05
- First posted
- 2018-10-24
- Last updated
- 2023-02-23
- Results posted
- 2023-02-23
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03718299. Inclusion in this directory is not an endorsement.